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Abstract
Background: Teneligliptin is a new FDA approved drug for treating Diabetes Mellitus. There are no reported
evidences for their identified degradation products and their effects on humans.
Methods: A simple and new stability indicating RP-HPLC method was developed and validated for identification of
Teneligliptin and its degradants on Kromasil 100- 5C18 (250×4.6mm, 5μm) column using pH 6.0 phosphate buffer
and acetonitrile (60:40 v/v) as a mobile phase in isocratic mode of elution at a flow rate of 1.0 mL/min. The column
effluents were monitored by a variable wavelength UV detector at 246 nm. The method was validated as per ICH
guidelines. Forced degradation studies of Teneligliptin were carried out under acidic, basic, neutral (peroxide), photo
and thermal conditions for 48 hours at room temperature. The degradation products were identified by HPLC and
characterized by UPLC with tandem mass spectroscopy (LC/MS/MS).
Results: UPLC MS/MS data shown major peaks, observed at 375.72, 354.30, 310.30, 214.19, 155.65, 138.08 and
136.18 m/z.
Conclusion: Degradation was observed in base, peroxide and thermal stressed samples, but not in acid and
photolytic stressed samples.
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Background
Teneligliptin is a novel drug, which is used for the treat-
ment of type 2 diabetes mellitus. It is an antidiabetic
drug that belongs to dipeptidyl peptidase-4 inhibitors or
“gliptins” (Kishimoto 2013). Chemically, it is {(2S, 4S)-4-
[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-
pyrrolidinyl} (1, 3-thiazolidin-3-yl) methanone (Fig. 1).
Teneligliptin exerts its activity for 24 h, with elevation
of activated glucagon-like peptide 1 (GLP-1) levels by
suppressing postprandial hyperglycemia after the meals
(Goda and Kadowaki 2013; Ideta et al. 2015; Bronson et
al. 2013). Significant decrease in hemoglobin A1c
(HbA1c), fasting blood glucose, and postprandial blood
glucose levels was observed in type 2 diabetic patients
taking teneligliptin for 12 weeks (Goda and Kadowaki
2013). This drug showed a promising effect in stabiliz-
ing the glycemic fluctuations throughout the day and
suppressing the diabetic complications (Ideta et al.
2015). Teneligliptin is approved for use in India, Japan,
and Korea in 2012 (Bronson et al. 2013). Although the
drug entered the market, there is no much information
available about its degradation studies and its degraded
products. Few have reported its metabolism and phar-
macokinetic studies (Halabi et al. 2013; Reddy and Rao
2014; Luhar et al. 2016; Shanthikumar et al. 2015).
Identification of the degraded products helps in future
metabolic studies and also related impurity determin-
ation during its bulk synthesis. In the present study, we
have focused our research into two stages: (1) to de-
velop and validate a reversed-phase HPLC (RP-HPLC)
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method for identifying the teneligliptin and its degrad-
ation products formed during various forced conditions
as per the ICH guidelines (Asian Guideline for Validation
of Analytical Procedure Adopted from ICH guideline,
Q2A27, and ICH Q2B 1994) and (2) identification of the
degraded products obtained and their characterization
using ultra-performance liquid chromatography (UPLC)
with tandem mass spectroscopy (LC/MS/MS).
Methods
Materials and reagents
HPLC grade acetonitrile (Lichrosolv®, Merck Life Science,
Pvt. Ltd., Mumbai, India), HPLC water (Lichrosolv®, Merck
Life Science, Pvt. Ltd., Mumbai, India), formic acid and
potassium dihydrogen o-phosphate (Thermo Fisher Scien-
tific Pvt. Ltd., Mumbai, India), and sodium hydroxide (S D
Fine-Chem. Ltd., Mumbai, India) were used for the study.
Teneligliptin pure drug and its tablet formulation were
obtained from Ajanta Pharma Limited, Mumbai, India.
Apparatus
The HPLC system (Agilent Technologies, Compact LC-
G4286A made in Germany) with variable wavelength UV
detector was used. Reversed-phase Kromasil® 100-5-C18
(250 × 4.6 mm, 5-μm particle size) column was used for
chromatographic separation. The chromatographic and
integrated data were recorded using EZChrom Elite Com-
pact Software in computed system (Version 3.30B, Sr. no.
08051601100, Scientific Software, Inc.). For the LC/MS
studies, UPLC system consisting of gradient mode pump
with column Acquity UPLC@ BEH C18 (1.7 μm, 2.1 ×
50 mm) detected using photo diode array (PDA) detector
range 200–400 nm was used. The mass spectrum with
electrospray ionization (ESI) mode of ionization was used
for the study (LC/MS/MS (Waters, XEVO-TQD).
Chromatographic conditions
Chromatographic separation was achieved on Kromasil®
100-5-C18 using a mobile phase consisting of a mixture of
pH 6.0 phosphate buffer and acetonitrile (60:40 v/v) under
isocratic mode of elution. The mobile phase was prepared
and filtered through membrane filters (0.45 μm) and soni-
cated for 30 min prior to use. Separation was performed
using 1 mL/min flow rate at room temperature, and the
run time was 25 min. The injection volume was 20 μL
and the detection wavelength set at 246 nm.
LC/MS conditions
Chromatographic separation was achieved on Acquity
UPLC@ BEH C18 1.7 μm, 2.1 × 50 mm using the gradi-
ent mobile phase consisting of A (10 % acetonitrile in
water with 0.1 % formic acid) and B (90 % acetonitrile
with 0.1 % formic acid). A flow rate of 0.3 mL/min is
maintained for the study. The eluted components were
detected using PDA at a range of 200–400 nm. The
products were ionized by ESI mode for their mass data.
Sample preparation
1000 μg/mL solution of teneligliptin was prepared by
dissolving the required amount of the drug in methanol.
The solution was adequately diluted with methanol for








Fig. 1 Structure of teneligliptin
Table 1 System suitability of teneligliptin










Table 2 Linearity of teneligliptin






Fig. 2 Linearity of teneligliptin
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Stability sample preparation
The collected samples of acid and base hydrolysis
were neutralized with sodium hydroxide and hydro-
chloric acid, respectively. Further dilution was carried
out with methanol and the remaining stressed sam-




The teneligliptin was subjected to forced degradation by
acid hydrolysis using 0.1 N HCl maintained at 35 °C for
48 h. The sample after the stress was neutralized with so-
dium hydroxide and diluted with methanol and filtered
through a 0.45-μm membrane before its analysis.
Base degradation
The teneligliptin was subjected to forced degradation
by base hydrolysis using 0.1 N NaOH maintained at
35 °C for 48 h. The sample after the stress was neu-
tralized with hydrochloric acid and diluted with
methanol and filtered through a 0.45-μm membrane
before its analysis.
Hydrogen peroxide (neutral) degradation
Forced degradation of teneligliptin was studied under
the influence of (3 %) hydrogen peroxide maintained at
35 °C for 48 h. The stressed sample was diluted with
methanol and filtered through a 0.45-μm membrane be-
fore its analysis.
Photolytic degradation
The influence of UV light on the stability of teneligliptin
was studied by exposing the sample in UV light at
365 nm for 48 h. The stressed sample was diluted with
methanol and filtered through a 0.45-μm membrane be-
fore its analysis.
Thermolysis degradation
The effect of increased temperature on teneligliptin was
studied by heating the sample at 69 °C for 48 h in a
refluxing apparatus. The stressed sample was diluted
with methanol and filtered through a 0.45-μm mem-
brane before its analysis.
Validation
System suitability
The system suitability was determined by six injections
of teneligliptin (300 μg/mL). The developed method was
found to be suitable for use as the tailing factor and peak
resolution for teneligliptin were within the limits.
Table 3 Precision results of teneligliptin

























80 200 100 300 1276 102.5
100 200 200 400 1632 96.5
120 200 300 500 2089 101.8
Table 5 LOD and LOQ results of teneligliptin
Calibration
equation
SD of the lowest
concentration in linearity
LOD (μg/mL) LOQ (μg/mL)
Y= 4.105x+ 22.81 5.03 4.04 12.259
Fig. 3 Typical HPLC chromatograms of teneligliptin and its degradation
products formed. a Pure drug solution. b 0.1 N HCl. c 0.1 N NaOH. d 3 %
hydrogen peroxide. e Photolysis UV light 365 nm. f Thermal 60 °C
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Linearity
The linearity of teneligliptin was studied from the stand-
ard concentrations ranging from 100 to 500 μg/mL. The
calibration curve of peak intensity versus concentration
was plotted, and correlation coefficient and regression
line equation were determined.
Precision
The precision of the method was determined by six (n = 6)
injections of teneligliptin (300 μg/mL), and the % RSD of
peak areas were calculated. The obtained RSD was within
the range (≤2).
Accuracy
The recovery of the method was determined by
adding a known amount of the drug to the stand-
ard concentration. The recovery was performed at
three levels of 80, 100, and 120 % of teneligliptin
standard concentration. The three samples were
prepared for each recovery level, and % recoveries
were calculated.
Limits of detection (LOD) and limit of quantification (LOQ)
The LOD and LOQ are the lowest level and lowest con-
centration of the analyte, respectively, in a sample that
would yield signal-to-noise ratios of 3.3 for LOD and 10






Time (h) Drug peak Degraded product peaks
Rt Peak
intensity
Peak 1 Peak 2
Rt Intensity Rt Intensity
1 Acid 0.1 N HCl 48 5.035 594.73 – – – –
2 Base 0.1 N NaOH 48 5.177 364.46 2.966 312.129 – –
3 Oxidative 0.3 % H2O2 48 5.299 1899.8 2.519 846.61 2.979 857.45
4 Light UV light 48 5.150 457.29 – – – –
5 Temperature 60 °C 48 5.140 600.41 3.033 46.65 – –
Rt retention time
Fig. 4 UPLC data of teneligliptin and its degradation products under
base stress
Fig. 5 UPLC data of teneligliptin and its degradation products under
hydrogen peroxide stress
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for LOQ. These are determined from the standard devi-
ation of the peak response and the slope of the calibra-
tion curve.
Results
Method development and optimization of
chromatographic conditions
Initially, 50:50 % v/v of methanol and water was tried
on Kromasil® 100-5-C18 as a mobile phase at 1 mL/
min flow rate and we observed that the peak was not
eluted in this mobile phase. Then, 50:50 % v/v pH 7.4
phosphate buffer (basic) and acetonitrile was tried as
a mobile phase on the same column at 1 mL/min
flow rate. The peak was eluted with poor resolution
and low intensity for high concentration (1000 μg/
mL) of the drug. Then, 50:50 % v/v pH 6 phosphate
buffer (acidic) and acetonitrile was tried as a mobile
phase on Kromasil® 100-5-C18, and greater intensity
and peak broadening were observed. Then, for better
resolution, 60:40 % v/v pH 6 phosphate buffer and
acetonitrile was modified as a mobile phase at 1 mL/
min flow rate. Sharp peak, good intensity, and good
retention time were observed in isocratic mode of
elution. The system suitability was performed, and the
results were found to be within the limits (Table 1).
Linearity with 0.99 regression coefficient was observed
at the concentration range of 100–500 μg/mL tabu-
lated in Table 2, and the calibration curve is depicted
in Fig. 2. The method was validated for the parame-
ters, precision, accuracy, and LOD-LOQ as per the
guidelines and tabulated the results in Tables 3, 4,
and 5, respectively. The results of validation were
within the limits.
Stability studies
Teneligliptin was stressed under different conditions,
and the samples were subjected to HPLC separation.
Significant degradation product peaks were observed in
basic, neutral (hydrogen peroxide), and thermolysis con-
ditions. The teneligliptin was found to be stable under
acidic and photolysis conditions. The chromatograms of
pure drug and its stressed samples are shown in Fig. 3.
The peak intensities and retention times of the degraded
product peaks during stress conditions are tabulated in
Table 6. The UPLC data is depicted in Figs. 4, 5, and 6
for the base-, hydrogen peroxide-, and thermally stressed
samples, respectively. The respective mass spectra are
shown in Figs. 7, 8, and 9. From the mass spectral data,
the fragmentation pattern of teneligliptin was depicted.
The fragmentation patterns of the base-, peroxide-, and
Fig. 6 UPLC data of teneligliptin and its degradation products under
thermal stress
Fig. 7 LC/MS/MS-ESI data of teneligliptin and its degradation
products under base stress
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thermally stressed teneligliptin are depicted in Figs. 10,
11, and 12, respectively.
Characterization of the degradation products
The molecular ion peak for teneligliptin was observed at
427.22 in ESI mode. In the base-stressed sample, the
fragments of 354.30 at a retention time of 1.195 min,
310.30 and 214.19 at a retention time of 1.345 min, and
178.73 and 155.65 at a retention time of 1.205 min were
observed. In the peroxide-stressed sample, the fragments
of 138.08 and 136.18 were observed at a retention time
of 1.666 and 1.467 min, respectively. In the thermally
stressed sample, the fragments of 375.72 at a retention
time of 0.455 min and 214.20, 310.31, and 155.69 at a
retention time of 1.325 min were observed. There are no
degradation peaks for teneligliptin in acid- and UV-stressed
conditions.
Discussion
Teneligliptin is an antidiabetic drug recently approved
by the FDA. There are no reports available for the stabil-
ity of the drug and their possible degraded products till
date. In the present research work, we aimed to perform
stability studies on teneligliptin and develop and validate
a method for its estimation and identification by RP-
HPLC. A new RP-HPLC method was developed and
validated for teneligliptin as per the ICH guidelines and
used as a stability-indicating method. The teneligliptin
pure drug was used for the study and stressed under
Fig. 8 LC/MS/MS-ESI data of teneligliptin and its degradation
products under hydrogen peroxide stress
Fig. 9 LC/MS/MS-ESI data of teneligliptin and its degradation






































Reactions & Conditions: i. Reflux under basic medium with 0.1 N NaOH at 35oC for 48 hours.
Fig. 10 Fragmentation pattern depiction of teneligliptin under base
stress
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acid, base, neutral (hydrogen peroxide), UV photolysis,
and thermal conditions. The HPLC analysis of the
stressed samples has shown that no degradation oc-
curred under the influence of acid and UV light. But the
stressed samples under base, peroxide, and thermal
have presence of the degraded products, which was
observed as separate peaks in HPLC other than the
teneligliptin. The obtained degraded samples were
further analyzed by UPLC/MS/MS, to identify the
products formed. The major molecular ion fragments
formed for all the three stress conditions are differ-
ent except 310.30 ((4-(4-(1-aminovinyl)piperazin-1-
yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone), 214.19 (N,N-
diethyl-1-phenyl-1H-pyrazol-5-amine), and 155.65 (1-(pyr-
rolidin-3-yl)piperazine) were observed in both base and




rolidin-2-yl)(thiazolidin-3-yl)methanone) molecular ion peak
was observed in base condition and thermal condition,
respectively. The products formed with photolytic stress
were completely different with molecular ions at 138.08
(N,N-diethyl-1H-pyrazol-5-amine) and 136.18 (2-amino-
N-(mercaptomethyl)-N-methylacetamide), which are not
observed in other stress conditions. From the data, it
is observed that comparatively less degradation oc-
curred for photolysis stress than for base and thermal
stress. The fragmentation pattern shows that the de-
graded products are similar for the base and thermal
stress samples. Further study is required for determin-
ing the degraded products’ toxicity by quantifying the
samples.
Conclusions
The present study helps in identifying the degraded
products of teneligliptin in bulk and formulations,
during their storage and transport conditions. This
research work is the first to report its stability stud-
ies with degraded product identification, which is
helpful for determining the toxicity of the degraded
products and also to caution the storage conditions.
The products formed could also be the starting ma-
terials during its synthesis, which has to be studied.
Further study is required for establishing the toxicity
profile of the degraded products, which is under
process.
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Reactions & Conditions: i. Reflux at 60oC for 48 hours.
Fig. 12 Fragmentation pattern depiction of teneligliptin under
thermal stress
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